Pantua, H., Diao, J., Ultsch, M., Hazen, M., Mathieu, M., McCutcheon, K., Takeda, K., Date, S., Cheung, T.K., Phung, Q., Hass, P., Arnott, D., Hongo, J.A., Matthews, D.J., Brown, A., Patel, A.H., Kelley, R.F., Eigenbrot, C. and Kapadia, S.B. (2013) Glycan Shifting on Hepatitis C Virus (HCV) E2 Glycoprotein Is a Mechanism for Escape from Broadly Neutralizing Antibodies. Journal of Molecular Biology, 425, 1899-1914.
https://doi.org/10.1016/j.jmb.2013.02.025

has been cited by the following article:

• TITLE: Monitoring the Treatment of Hepatitis C Viral Infection by Molecular Techniques

  AUTHORS: Mohamed Nabil, Mohammed H. Saiem Al-Dahr, Ahmed Haridi, Waleed S. Mohamed, Ezeldine K. Abdalhabib, Bi Bi Zainab Mazahari

  KEYWORDS: Monitoring, Hepatitis C Infection, RNA, Treatment, Molecular Techniques

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.7 No.11, November 8, 2019

  ABSTRACT: The prevalence of Hepatitis C viral infection in Egypt is the highest rate in the world. It is a major public health problem in Egypt. The objective of this study was to detect the clearance of HCV-RNA in Egyptian patients who were recommended for combination therapy of pyglated interferon α 2a and ribavirin (PEG-interferon/Ribavirin). Ninety-five positive HCV-IgG cases were tested for HCV-RNA at baseline and at weeks 4, 12, 24, 48 and 72 of treatment with PEG-interferon α 2a/Ribavirin. The correlations between the viral parameters during and after treatment were evaluated. Patients recommended receiving PEG-interferon 2a/ribavirin combination therapy showed high response rate determined as 71.9% achieved Sustained Virological Response (SVR) from total patients, and 71.4% from patients who received 48 weeks therapy. In general, the employment of TMA provided us the accuracy of results with confidence in our work. There was a significant relation (p